Jon Congleton
2022 - Mineralys Therapeutics
In 2022, Jon Congleton earned a total compensation of $1.7M as Chief Executive Officer at Mineralys Therapeutics.
Compensation breakdown
| Bonus | $72,450 |
|---|---|
| Non-Equity Incentive Plan | $120,750 |
| Salary | $416,667 |
| Stock Awards | $1,118,118 |
| Other | $12,200 |
| Total | $1,740,185 |
Congleton received $1.1M in stock awards, accounting for 64% of the total pay in 2022.
Congleton also received $72.5K in bonus, $120.8K in non-equity incentive plan, $416.7K in salary and $12.2K in other compensation.
Rankings
In 2022, Jon Congleton's compensation ranked 1,977th out of 5,736 executives tracked by ExecPay. In other words, Congleton earned more than 65.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,977 out of 5,736 | 66th |
Division Manufacturing | 1,055 out of 3,125 | 66th |
Major group Chemicals And Allied Products | 450 out of 1,416 | 68th |
Industry group Drugs | 412 out of 1,317 | 69th |
Industry Pharmaceutical Preparations | 299 out of 963 | 69th |
Source: SEC filing on April 9, 2024.
Congleton's colleagues
We found two more compensation records of executives who worked with Jon Congleton at Mineralys Therapeutics in 2022.